- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
CDC25C Antibody (ascites)Mouse Monoclonal Antibody (Mab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AM1908a | 0.1 ml 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
CDC25C Antibody (ascites) - Product info | |
| Application | WB
|
| Primary Accession | P30307 |
| Other Accession | NP_001781.2, NP_073720.1 |
| Reactivity | Human |
| Concentration | Crude ascites |
| Isotype | IgG1,k |
| Clone Names | 233CT9.6.6 |
| Calculated MW | 53365 Da |
CDC25C Antibody (ascites) - Additional info | |
| Gene ID 995 | |
| Other Names CDC25C; M-phase inducer phosphatase 3; Dual specificity phosphatase Cdc25C | |
| Target/Specificity This CDC25C monoclonal antibody is generated from mouse immunized with CDC25C recombinant protein. | |
| Dilution WB~~1:1000~8000 | |
| Format Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions CDC25C Antibody (ascites) is for research use only and not for use in diagnostic or therapeutic procedures. | |
CDC25C Antibody (ascites) - Protein Information | |
| Name CDC25C | |
| Function Functions as a dosage-dependent inducer in mitotic control. Tyrosine protein phosphatase required for progression of the cell cycle. When phosphorylated, highly effective in activating G2 cells into prophase. Directly dephosphorylates CDK1 and activates its kinase activity | |
| Cellular Location Nucleus. | |
CDC25C Antibody (ascites) - Related products
AM1908a: CDC25C Antibody (ascites)
AP7862b: CDC25C Antibody (C-term)
AP7862d: CDC25C Antibody (Center)
RI10921: CDC25C predesign siRNA
DC04797: Human CDC25C cDNA Clone
LY11518a: CDC25C Over-expression Lysate
BP7862b: CDC25C Antibody (C-term) Blocking Peptide
BP7862d: CDC25C Antibody (Center) Blocking Peptide
AT1458a: CDC25C Antibody (monoclonal) (M01)
CDC25C Antibody (ascites) - Application data
-
Western blot analysis of CDC25C (arrow) using CDC25C (Cat. #AM1908a). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the CDC25C gene.
CDC25C Antibody (ascites) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
This gene is highly conserved during evolution and it plays a key role in the regulation of cell division. The encoded protein is a tyrosine phosphatase and belongs to the Cdc25 phosphatase family. It directs dephosphorylation of cyclin B-bound CDC2 and triggers entry into mitosis. It is also thought to suppress p53-induced growth arrest. Multiple alternatively spliced transcript variants of this gene have been described, however, the full-length nature of many of them is not known. [provided by RefSeq].
REFERENCES
Moon, D.O., et al. Oncol. Rep. 24(1):271-276(2010) Liu, C.Y., et al. Carcinogenesis 31(7):1259-1263(2010) Olson, J.E., et al. Breast Cancer Res. Treat. (2010) In press : Franckhauser, C., et al. PLoS ONE 5 (7), E11798 (2010) : Wang, Z., et al. BMC Cancer 10, 233 (2010) :
